PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16130750-1 2005 Fosinopril sodium presents a prodrug for the active angiotensin converting enzyme (ACE) inhibitor, fosinoprilat. Fosinopril 0-17 angiotensin I converting enzyme Homo sapiens 52-81 17337423-1 2007 Fosinopril sodium, a phosphinic acid derivative is an angiotensin converting enzyme (ACE) inhibitor, which had been employed for the treatment of hypertension and congestive heart failure; long tem use of ACE inhibitor often result in stress ulcers due to which H(2) receptor antagonists are also concurrently prescribed. Fosinopril 0-17 angiotensin I converting enzyme Homo sapiens 54-83 17337423-1 2007 Fosinopril sodium, a phosphinic acid derivative is an angiotensin converting enzyme (ACE) inhibitor, which had been employed for the treatment of hypertension and congestive heart failure; long tem use of ACE inhibitor often result in stress ulcers due to which H(2) receptor antagonists are also concurrently prescribed. Fosinopril 0-17 angiotensin I converting enzyme Homo sapiens 85-88 17337423-1 2007 Fosinopril sodium, a phosphinic acid derivative is an angiotensin converting enzyme (ACE) inhibitor, which had been employed for the treatment of hypertension and congestive heart failure; long tem use of ACE inhibitor often result in stress ulcers due to which H(2) receptor antagonists are also concurrently prescribed. Fosinopril 0-17 angiotensin I converting enzyme Homo sapiens 205-208 16634995-2 2006 We examined the efficacy and tolerability of fosinopril, an ACE inhibitor with dual hepatic and renal clearance, in 38 type 2 diabetic patients with moderate renal impairment (plasma creatinine 130-300 micromol/l) over a 2-year period. Fosinopril 45-55 angiotensin I converting enzyme Homo sapiens 60-63 16631159-6 2006 Captopril, ramipril, enalapril, lisinopril and fosinopril were assessed by measuring: their inhibiting effect on the MPO/H(2)O(2)/Cl(-) system, the accumulation of compound II, which reflects the inhibition of the synthesis of HOCl and the LDL oxidation by MPO in presence of several concentrations of ACE inhibitors. Fosinopril 47-57 angiotensin I converting enzyme Homo sapiens 302-305 16915750-3 2006 OBJECTIVE: Aim of the study was to determine the effect of the ACE inhibitor Fosinopril on the intima-media thickness of the common carotid artery and on the left ventricle mass after 9-month treatment of hypertensive patients. Fosinopril 77-87 angiotensin I converting enzyme Homo sapiens 63-66 16130750-1 2005 Fosinopril sodium presents a prodrug for the active angiotensin converting enzyme (ACE) inhibitor, fosinoprilat. Fosinopril 0-17 angiotensin I converting enzyme Homo sapiens 83-86 16130750-2 2005 The dual elimination of fosinoprilat by the liver and the kidney distinguishes fosinopril from other angiotensin converting enzyme inhibitors. Fosinopril 24-34 angiotensin I converting enzyme Homo sapiens 101-130 15938534-0 2005 [Effects of ACE inhibitor fosinopril on a 24-h profile of arterial pressure in hypertensive patients with obesity and hypercholesterolemia]. Fosinopril 26-36 angiotensin I converting enzyme Homo sapiens 12-15 16502517-1 2005 Angiotensin converting enzyme inhibitor fosinopril was given for 12 weeks to 92 patients with hypertension and metabolic syndrome. Fosinopril 40-50 angiotensin I converting enzyme Homo sapiens 0-29 12925048-9 2003 CONCLUSIONS: Hydrochlorothiazide 12.5 mg/day, when added to background ACE inhibitor therapy with fosinopril in hypertensive diabetic patients, resulted in a metabolic profile that was similar, if not superior on certain parameters, in comparison with indapamide 2.5 mg/day. Fosinopril 98-108 angiotensin I converting enzyme Homo sapiens 71-74 15744357-3 2004 Apart from appropriate clinical measures to be taken, the choice of the ACE inhibitor seems to be of crucial importance as some (fosinopril, perindopril) produce less hypotension than others. Fosinopril 129-139 angiotensin I converting enzyme Homo sapiens 72-75 12602460-4 2002 The main aim of the FOSIDIAL study is to assess the efficacy and safety of fosinopril, an angiotensin converting enzyme (ACE) inhibitor, in reducing the mortality and cardiovascular events in haemodialysis patients presenting with left ventricular hypertrophy. Fosinopril 75-85 angiotensin I converting enzyme Homo sapiens 90-119 12602460-4 2002 The main aim of the FOSIDIAL study is to assess the efficacy and safety of fosinopril, an angiotensin converting enzyme (ACE) inhibitor, in reducing the mortality and cardiovascular events in haemodialysis patients presenting with left ventricular hypertrophy. Fosinopril 75-85 angiotensin I converting enzyme Homo sapiens 121-124 11826546-4 2001 OBJECTIVE OF TRIAL: To assess the effectiveness and tolerance of the modern long-acting ACE inhibitor--fosinopril--in the treatment of mild and medium severe hypertension and its effect on some anthropometric and laboratory parameters. Fosinopril 103-113 angiotensin I converting enzyme Homo sapiens 88-91 11560874-0 2001 Mechanism of intestinal absorption and renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in cell cultures. Fosinopril 117-127 angiotensin I converting enzyme Homo sapiens 78-81 11064182-4 2000 We present preliminary findings from echocardiographic and platelet activation studies in 16 HIV-positive, cocaine abusing patients, as well as tolerability and efficacy studies of the ACE-inhibitor, fosinopril, for the treatment of cocaine abuse in both HIV-positive (n=6) and HIV-negative (n=5) methadone-maintained cocaine abusers. Fosinopril 200-210 angiotensin I converting enzyme Homo sapiens 185-188 11436209-2 2001 The purpose of this prospective study was to evaluate changes of left ventricular (LV) myocardial mass, as well as diastolic filling properties, in hypertensive patients treated with the ACE inhibitor fosinopril. Fosinopril 201-211 angiotensin I converting enzyme Homo sapiens 187-190 11030016-6 2000 Differences among the ACE inhibitors in lipophilicity are described; fosinopril has the greatest lipophilicity and lisinopril the least. Fosinopril 69-79 angiotensin I converting enzyme Homo sapiens 22-25 11105370-2 2000 She had been on fosinopril, an angiotensin-converting enzyme inhibitor (ACE inhibitor) for 4 years. Fosinopril 16-26 angiotensin I converting enzyme Homo sapiens 72-75 11501170-1 2000 AIM: To study the influence of angiotensin (Ang) II receptor antagonist (AT1) valsartan and angiotensin-converting enzyme (ACE) inhibitor fosinopril on the cardiac hypertrophy induced by catecholamine. Fosinopril 138-148 angiotensin I converting enzyme Homo sapiens 123-126 11329095-0 1999 The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril 57-67 angiotensin I converting enzyme Homo sapiens 37-40 10999650-2 2000 We investigated prospectively whether the response to the ACE inhibitor fosinopril varied according to the ACE genotype in previously untreated Greek hypertensive patients. Fosinopril 72-82 angiotensin I converting enzyme Homo sapiens 58-61 10999650-2 2000 We investigated prospectively whether the response to the ACE inhibitor fosinopril varied according to the ACE genotype in previously untreated Greek hypertensive patients. Fosinopril 72-82 angiotensin I converting enzyme Homo sapiens 107-110 10999650-9 2000 In conclusion, the ACE gene genotype was shown to influence the response to fosinopril in hypertensive patients. Fosinopril 76-86 angiotensin I converting enzyme Homo sapiens 19-22 10666408-6 2000 The effect was dose-dependent and was attributable to ACE inhibition, given that other ACE inhibitors, such as idrapril or fosinopril, and losartan, an antagonist of the angiotensin II AT(1) receptor, caused a comparable reduction in TF activity. Fosinopril 123-133 angiotensin I converting enzyme Homo sapiens 54-57 10856268-2 2000 The in vitro and in vivo inhibitory potency of omapatrilat and the specific ACE inhibitor fosinopril toward the 2 active sites of ACE (called N- and C-domains) was investigated with the use of 3 substrates: angiotensin I, which is equally cleaved by the 2 ACE domains; hippuryl-histidyl-leucine, specific synthetic substrate of the C-domain in high- salt conditions; and a newly synthesized specific substrate of the N-domain designed by acetylating the lysine residue of AcSDKP. Fosinopril 90-100 angiotensin I converting enzyme Homo sapiens 76-79 10856268-2 2000 The in vitro and in vivo inhibitory potency of omapatrilat and the specific ACE inhibitor fosinopril toward the 2 active sites of ACE (called N- and C-domains) was investigated with the use of 3 substrates: angiotensin I, which is equally cleaved by the 2 ACE domains; hippuryl-histidyl-leucine, specific synthetic substrate of the C-domain in high- salt conditions; and a newly synthesized specific substrate of the N-domain designed by acetylating the lysine residue of AcSDKP. Fosinopril 90-100 angiotensin I converting enzyme Homo sapiens 130-133 10856268-2 2000 The in vitro and in vivo inhibitory potency of omapatrilat and the specific ACE inhibitor fosinopril toward the 2 active sites of ACE (called N- and C-domains) was investigated with the use of 3 substrates: angiotensin I, which is equally cleaved by the 2 ACE domains; hippuryl-histidyl-leucine, specific synthetic substrate of the C-domain in high- salt conditions; and a newly synthesized specific substrate of the N-domain designed by acetylating the lysine residue of AcSDKP. Fosinopril 90-100 angiotensin I converting enzyme Homo sapiens 130-133 10194656-0 1999 Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin-converting enzyme inhibitor fosinopril in congestive heart failure. Fosinopril 125-135 angiotensin I converting enzyme Homo sapiens 85-114 10194656-3 1999 METHODS AND RESULTS: We investigated the effect of 12 weeks of treatment with the ACE inhibitor fosinopril on peripheral microvascular function in a double-blind, placebo-controlled study of 12 patients treated with fosinopril and 10 patients treated with placebo. Fosinopril 96-106 angiotensin I converting enzyme Homo sapiens 82-85 10194656-8 1999 CONCLUSIONS: These results suggest that long-term ACE inhibitor treatment with fosinopril in patients with CHF improves hemodynamic status to as far as the peripheral microvascular level in both the relaxed and nonrelaxed microcirculation of the lower leg. Fosinopril 79-89 angiotensin I converting enzyme Homo sapiens 50-53 10412878-1 1999 The aim of this study was to investigate the relationships between angiotensin-converting enzyme (ACE) activity in serum and skeletal muscle to blood pressure and the long-term antihypertensive effects of fosinopril and atenolol. Fosinopril 205-215 angiotensin I converting enzyme Homo sapiens 98-101 10412878-9 1999 In the fosinopril group, muscle ACE activity was not different during treatment than at baseline (-2. Fosinopril 7-17 angiotensin I converting enzyme Homo sapiens 32-35 9366279-0 1997 Treatment of heart failure with fosinopril: an angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion. Fosinopril 32-42 angiotensin I converting enzyme Homo sapiens 47-76 9923037-1 1998 Diffuse hypoxic pneumonia was found to be caused by angiotensin converting enzyme (ACE) inhibitors in two patients given enalapril and fosinopril for hypertension. Fosinopril 135-145 angiotensin I converting enzyme Homo sapiens 52-81 9923037-1 1998 Diffuse hypoxic pneumonia was found to be caused by angiotensin converting enzyme (ACE) inhibitors in two patients given enalapril and fosinopril for hypertension. Fosinopril 135-145 angiotensin I converting enzyme Homo sapiens 83-86 9822138-5 1998 The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET), discussed herein, supports the case for combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist in diabetic patients with hypertension. Fosinopril 4-14 angiotensin I converting enzyme Homo sapiens 138-167 9822138-5 1998 The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET), discussed herein, supports the case for combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist in diabetic patients with hypertension. Fosinopril 4-14 angiotensin I converting enzyme Homo sapiens 63-66 9822144-2 1998 These 2 studies, the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) and Appropriate Blood Pressure Control in Diabetes (ABCD), showed that angiotensin-converting enzyme (ACE) inhibitors may be preferable to calcium antagonists for managing hypertension in diabetic patients; they do not, however, show any harm attributable to calcium antagonists. Fosinopril 21-31 angiotensin I converting enzyme Homo sapiens 168-197 9822144-2 1998 These 2 studies, the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) and Appropriate Blood Pressure Control in Diabetes (ABCD), showed that angiotensin-converting enzyme (ACE) inhibitors may be preferable to calcium antagonists for managing hypertension in diabetic patients; they do not, however, show any harm attributable to calcium antagonists. Fosinopril 21-31 angiotensin I converting enzyme Homo sapiens 91-94 9446181-3 1997 A study is presented which investigates efficacy and tolerance of the ACE-inhibitor fosinopril in an unselected cohort of hypertensive outpatients older than 60 years over 12 weeks. Fosinopril 84-94 angiotensin I converting enzyme Homo sapiens 70-73 9736436-8 1998 In particular, the ACE inhibitor fosinopril may offer advantages because of its dual route of elimination, thus simplifying dosing in renally impaired patients. Fosinopril 33-43 angiotensin I converting enzyme Homo sapiens 19-22 9736438-5 1998 More recently, some studies have demonstrated the ability of ACE inhibitors (particularly fosinopril) to prevent the long-term development of CHF in patients treated acutely during MI and without baseline LV dysfunction. Fosinopril 90-100 angiotensin I converting enzyme Homo sapiens 61-64 9736439-10 1998 Only one ACE inhibitor, fosinopril, has been shown to be effective in normalizing ET-1 levels in clinically relevant situations, such as the long-term study of patients with CHF. Fosinopril 24-34 angiotensin I converting enzyme Homo sapiens 9-12 9366278-3 1997 The aim of the Italian multicenter study reported here is to compare the efficacy, safety, and tolerability of fosinopril, a novel angiotensin converting enzyme (ACE) inhibitor with a dual route of excretion, with chlorthalidone, the diuretic administered in the SHEP study, in 312 elderly patients with isolated systolic hypertension. Fosinopril 111-121 angiotensin I converting enzyme Homo sapiens 131-160 9366278-3 1997 The aim of the Italian multicenter study reported here is to compare the efficacy, safety, and tolerability of fosinopril, a novel angiotensin converting enzyme (ACE) inhibitor with a dual route of excretion, with chlorthalidone, the diuretic administered in the SHEP study, in 312 elderly patients with isolated systolic hypertension. Fosinopril 111-121 angiotensin I converting enzyme Homo sapiens 162-165 9366278-7 1997 In conclusion, the novel ACE inhibitor fosinopril is an effective and well-tolerated antihypertensive agent for use in elderly patients with isolated systolic hypertension and appears to be a suitable alternative for the treatment of isolated systolic hypertension. Fosinopril 39-49 angiotensin I converting enzyme Homo sapiens 25-28 9366279-6 1997 An ACE inhibitor with a dual route of excretion, such as fosinopril, may be especially useful in treating patients with CHF. Fosinopril 57-67 angiotensin I converting enzyme Homo sapiens 3-6 9366282-2 1997 In the present trial, the efficacy and tolerance of the ACE inhibitor fosinopril was examined over a period of 12 weeks in an open trial of hypertensive patients aged over 60 years with diastolic hypertension (diastolic blood pressure 95 to 110 mm Hg) and isolated systolic hypertension (ISH; systolic blood pressure 160 to 219 mm Hg, diastolic blood pressure 80 to 94 mm Hg). Fosinopril 70-80 angiotensin I converting enzyme Homo sapiens 56-59 9366284-8 1997 In addition, analysis of more recent studies of the treatment of fosinopril in patients with mild to moderate CHF have been performed and have proved this newer ACE inhibitor to be cost-saving in these patients. Fosinopril 65-75 angiotensin I converting enzyme Homo sapiens 161-164 9366286-5 1997 The most recently introduced ACE inhibitor, fosinopril, is at least as effective as enalapril, and its dual and compensatory route of excretion is particularly advantageous in patients with renal insufficiency. Fosinopril 44-54 angiotensin I converting enzyme Homo sapiens 29-32 9186076-14 1997 We conclude that chronic ACE inhibition with fosinopril and lisinopril alone or in combination with furosemide lowers BP in older blacks and nonblacks with hypertension and chronic renal insufficiency. Fosinopril 45-55 angiotensin I converting enzyme Homo sapiens 25-28 9284425-4 1997 ACE inhibitors can be classified according to the ligand of the zinc ion of ACE, into 3 different structural types: (1) the first type such as captopril has a sulphhydryl moiety as the ligand; (2) the second type such as enalapril uses a carboxyl moiety as the ligand; (3) the third type such as fosinopril uses neither a sulphhydryl nor carboxyl group, but a phosphinic acid as the zinc binding moiety. Fosinopril 296-306 angiotensin I converting enzyme Homo sapiens 0-3 9284425-4 1997 ACE inhibitors can be classified according to the ligand of the zinc ion of ACE, into 3 different structural types: (1) the first type such as captopril has a sulphhydryl moiety as the ligand; (2) the second type such as enalapril uses a carboxyl moiety as the ligand; (3) the third type such as fosinopril uses neither a sulphhydryl nor carboxyl group, but a phosphinic acid as the zinc binding moiety. Fosinopril 296-306 angiotensin I converting enzyme Homo sapiens 76-79 9211084-2 1997 Fosinopril is the prodrug of the active diacid ACE inhibitor fosinoprilat. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 47-50 9105649-3 1997 ACE activity in serum and uncentrifuged skeletal muscle homogenates was measured with a fluorometric assay before and during treatment in 24 fosinopril-treated and 26 atenolol-treated hypertensives. Fosinopril 141-151 angiotensin I converting enzyme Homo sapiens 0-3 9195116-2 1997 Fosinopril is a phosphorus-containing ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 58-87 9195116-2 1997 Fosinopril is a phosphorus-containing ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 89-92 9037321-4 1997 The serum ACE activity was determined in the group treated with fosinopril. Fosinopril 64-74 angiotensin I converting enzyme Homo sapiens 10-13 8934359-0 1996 The angiotensin converting enzyme inhibitors fosinopril and enalapril differ in their central nervous effects in humans. Fosinopril 45-55 angiotensin I converting enzyme Homo sapiens 4-33 8931831-2 1996 The objectives of this study were to evaluate the effects of an ACE inhibitor (fosinopril) and a calcium antagonist (amlodipine) on the urinary albumin and transferrin excretion and their relationship to the blood pressure in essential hypertension. Fosinopril 79-89 angiotensin I converting enzyme Homo sapiens 64-67 8934359-12 1996 The effects diverging between enalapril and fosinopril indicate that access to human brain functions differs among the various types of ACE inhibitors. Fosinopril 44-54 angiotensin I converting enzyme Homo sapiens 136-139 8934359-3 1996 OBJECTIVE: To compare central nervous effects of the biochemically different ACE inhibitors fosinopril and enalapril in healthy men. Fosinopril 92-102 angiotensin I converting enzyme Homo sapiens 77-80 8720415-3 1996 Because increased platelet aggregation was shown in hypertensive patients, the effect of a new ACE inhibitor, fosinopril, on platelet aggregation was studied. Fosinopril 110-120 angiotensin I converting enzyme Homo sapiens 95-98 8934382-7 1996 PLAQUE HYPERTENSION LIPID-LOWERING ITALIAN STUDY (PHYLLIS): This trial is using a factorial design to explore the anti-atherosclerotic action of an angiotensin converting enzyme (ACE) inhibitor (fosinopril) versus a diuretic, and also intends to evaluate the possible benefits of associating antihypertensive therapy with a statin to induce lipid-lowering to prevent the progression of carotid atherosclerosis. Fosinopril 195-205 angiotensin I converting enzyme Homo sapiens 148-177 8797128-12 1996 Fosinopril caused a greater inhibition of ACE at the doses used in the present study, which was statistically significant. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 42-45 8861547-1 1996 Fosinopril is a phosphinic acid derivative which undergoes rapid hydrolysis after oral administration to the active diacid ACE inhibitor fosinoprilat. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 123-126 8861547-2 1996 Cardiotropic effects have been associated with the drug, and the compensatory dual elimination route of fosinopril via renal and hepatic systems offers an opportunity for ACE inhibitor treatment of hypertension in patients with renal or hepatic impairment. Fosinopril 104-114 angiotensin I converting enzyme Homo sapiens 171-174 11854791-0 1995 A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Fosinopril 37-47 angiotensin I converting enzyme Homo sapiens 105-108 7751424-1 1995 The single-dose and steady-state pharmacokinetics of the angiotensin-converting enzyme (ACE) inhibitor fosinopril and its active diacid, fosinoprilat, were evaluated in 6 healthy volunteers and 12 patients with alcoholic cirrhosis. Fosinopril 103-113 angiotensin I converting enzyme Homo sapiens 57-86 7658352-0 1995 Aggregation behavior of fosinopril sodium--a new angiotensin-converting enzyme inhibitor. Fosinopril 24-41 angiotensin I converting enzyme Homo sapiens 49-78 7658352-1 1995 Fosinopril sodium is an effective new angiotensin-converting enzyme (ACE) inhibitor that is very useful for the clinical treatment of hypertension. Fosinopril 0-17 angiotensin I converting enzyme Homo sapiens 38-67 7658352-1 1995 Fosinopril sodium is an effective new angiotensin-converting enzyme (ACE) inhibitor that is very useful for the clinical treatment of hypertension. Fosinopril 0-17 angiotensin I converting enzyme Homo sapiens 69-72 7771972-5 1995 However, fosinopril may be the preferred ACE inhibitor in patients with significant renal dysfunction because of a reduced requirement for dosage reduction. Fosinopril 9-19 angiotensin I converting enzyme Homo sapiens 41-44 7752642-1 1995 We determined whether inhibiting angiotensin-converting enzyme (ACE) with fosinopril or captopril induced the regression of atherosclerosis in hamsters. Fosinopril 74-84 angiotensin I converting enzyme Homo sapiens 33-62 7752642-1 1995 We determined whether inhibiting angiotensin-converting enzyme (ACE) with fosinopril or captopril induced the regression of atherosclerosis in hamsters. Fosinopril 74-84 angiotensin I converting enzyme Homo sapiens 64-67 7752642-2 1995 A pressor experiment demonstrated that 100 mg/kg fosinopril or captopril almost completely inhibited ACE activity in vivo. Fosinopril 49-59 angiotensin I converting enzyme Homo sapiens 101-104 7751424-1 1995 The single-dose and steady-state pharmacokinetics of the angiotensin-converting enzyme (ACE) inhibitor fosinopril and its active diacid, fosinoprilat, were evaluated in 6 healthy volunteers and 12 patients with alcoholic cirrhosis. Fosinopril 103-113 angiotensin I converting enzyme Homo sapiens 88-91 7882821-1 1994 OBJECTIVE: To determine whether the angiotensin-converting enzyme (ACE) inhibitor fosinopril can favorably alter cardiac function in non-insulin-dependent diabetes mellitus NIDDM) patients who have either normal blood pressure (BP) or mild, untreated hypertension. Fosinopril 82-92 angiotensin I converting enzyme Homo sapiens 36-65 7882821-1 1994 OBJECTIVE: To determine whether the angiotensin-converting enzyme (ACE) inhibitor fosinopril can favorably alter cardiac function in non-insulin-dependent diabetes mellitus NIDDM) patients who have either normal blood pressure (BP) or mild, untreated hypertension. Fosinopril 82-92 angiotensin I converting enzyme Homo sapiens 67-70 7882821-2 1994 RESEARCH DESIGN AND METHODS: Fifty-five NIDDM subjects with normal BP or mild, untreated hypertension were randomized to treatment with the ACE-inhibitor fosinopril or placebo for 6 months in a randomized, double-blind trial to determine the effect of fosinopril on echocardiographic measurements. Fosinopril 154-164 angiotensin I converting enzyme Homo sapiens 140-143 7986469-0 1994 Unchanged neurogenic vasoconstrictor response after exercise during angiotensin converting enzyme inhibition with fosinopril. Fosinopril 114-124 angiotensin I converting enzyme Homo sapiens 68-97 7528851-10 1994 In conclusion, the ACE inhibitors captopril and fosinopril inhibited development of atherosclerosis in hypercholesterolemic minipigs. Fosinopril 48-58 angiotensin I converting enzyme Homo sapiens 19-22 7919557-1 1994 OBJECTIVE: To report a case of chronic, nonproductive cough secondary to the angiotensin-converting enzyme (ACE) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, fosinopril. Fosinopril 201-211 angiotensin I converting enzyme Homo sapiens 77-106 7980708-4 1994 The same dose of fosinopril and captopril inhibited the angiotensin I pressor response, indicating these agents suppressed ACE activity in vivo. Fosinopril 17-27 angiotensin I converting enzyme Homo sapiens 123-126 7919557-1 1994 OBJECTIVE: To report a case of chronic, nonproductive cough secondary to the angiotensin-converting enzyme (ACE) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, fosinopril. Fosinopril 201-211 angiotensin I converting enzyme Homo sapiens 108-111 7919557-1 1994 OBJECTIVE: To report a case of chronic, nonproductive cough secondary to the angiotensin-converting enzyme (ACE) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, fosinopril. Fosinopril 201-211 angiotensin I converting enzyme Homo sapiens 186-189 7919557-13 1994 We report a case of cough following the administration of quinapril, with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension. Fosinopril 142-152 angiotensin I converting enzyme Homo sapiens 128-131 7919557-15 1994 Frequency of cough is variable and although this complication has been described as a class effect, patients with a persistent, severe ACE inhibitor-induced cough may benefit from a trial of fosinopril therapy. Fosinopril 191-201 angiotensin I converting enzyme Homo sapiens 135-138 8285182-11 1993 Thus, fosinopril use was associated with a less frequent, less severe cough in patients who experienced cough while taking other ACE inhibitors. Fosinopril 6-16 angiotensin I converting enzyme Homo sapiens 129-132 8281674-0 1994 Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Fosinopril 46-63 angiotensin I converting enzyme Homo sapiens 0-29 8281674-2 1994 METHODS AND RESULTS: We conducted a randomized, double-blind, placebo-controlled trial to assess the effect of fosinopril, a novel angiotensin-converting enzyme inhibitor, in restenosis prevention after percutaneous transluminal coronary angioplasty (PTCA). Fosinopril 111-121 angiotensin I converting enzyme Homo sapiens 131-160 7957538-0 1994 Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition. Fosinopril 77-87 angiotensin I converting enzyme Homo sapiens 31-60 7957538-8 1994 The change in insulin sensitivity and serum triglycerides during treatment with fosinopril was related to angiotensin-converting enzyme inhibition in serum. Fosinopril 80-90 angiotensin I converting enzyme Homo sapiens 106-135 8052432-1 1994 A multicentre, randomized, placebo-controlled study was performed in 39 adult patients with biopsy-proven IgA nephropathy with the aim of comparing the effects of the ACE inhibitor fosinopril and placebo on proteinuria. Fosinopril 181-191 angiotensin I converting enzyme Homo sapiens 167-170 8285179-8 1993 Fosinopril appears to have a cardiotropic effect that causes improved left ventricular diastolic performance; this effect is unique among currently available ACE inhibitors. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 158-161 8285181-2 1993 Our recent data show that in patients with proteinuric renal disease, serum levels of total cholesterol and lipoprotein(a) [Lp(a)] may be lowered during treatment with an ACE inhibitor, fosinopril sodium. Fosinopril 186-203 angiotensin I converting enzyme Homo sapiens 171-174 8285182-5 1993 Fosinopril is a long-acting ACE inhibitor with a unique chemical structure and an elimination profile that is associated with stable clearance, regardless of the degree of renal impairment. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 28-31 1834450-0 1991 Fosinopril (Staril)--another ACE inhibitor. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 29-32 1534664-3 1992 In this study, the hemodynamic effects of the angiotensin converting enzyme inhibitor fosinopril were assessed at rest and at peak upright bicycle exercise by first-pass radionuclide cineangiography in 12 patients with essential hypertension. Fosinopril 86-96 angiotensin I converting enzyme Homo sapiens 46-75 1534664-7 1992 The unique cardiotropic response to fosinopril may reflect its effects on the myocardial renin-angiotensin system, and suggests that this agent may offer a therapeutic advantage compared with other angiotensin converting enzyme inhibitors. Fosinopril 36-46 angiotensin I converting enzyme Homo sapiens 198-227 1372856-2 1992 Fosinopril is a phosphinic acid prodrug which, after oral administration, undergoes rapid hydrolysis to its active diacid, the angiotensin converting enzyme (ACE) inhibitor fosinoprilat. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 127-156 1372856-2 1992 Fosinopril is a phosphinic acid prodrug which, after oral administration, undergoes rapid hydrolysis to its active diacid, the angiotensin converting enzyme (ACE) inhibitor fosinoprilat. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 158-161 1372856-7 1992 Generally, fosinopril is well tolerated and adverse events associated with the drug are usually mild and similar to those associated with other ACE inhibitors. Fosinopril 11-21 angiotensin I converting enzyme Homo sapiens 144-147 1533588-1 1992 The effect of the new ACE-inhibitor, fosinopril, on insulin sensitivity (SI), glucose homoeostasis and lipid profile has been examined in 24 young, healthy, normotensive men. Fosinopril 37-47 angiotensin I converting enzyme Homo sapiens 22-25 1533588-4 1992 Compared with control values at the end of the run-in placebo phase, fosinopril reduced plasma ACE activity (from 106 to 24 nmol.ml-1.min-1), Significantly increased plasma potassium and lowered upright systolic blood pressure. Fosinopril 69-79 angiotensin I converting enzyme Homo sapiens 95-98 1533588-7 1992 The findings indicate that in healthy lean humans, ACE inhibition with fosinopril is neutral with regard to lipoprotein and carbohydrate metabolism, and that it may slightly enhance cellular glucose disposal. Fosinopril 71-81 angiotensin I converting enzyme Homo sapiens 51-54 1318861-2 1992 We have studied the possible dissociation of the fosinopril-ACE complex during the storage of serum samples from healthy male volunteers given a single dose of fosinopril. Fosinopril 49-59 angiotensin I converting enzyme Homo sapiens 60-63 1283426-9 1992 Fosinopril, a new phosphorus-containing ACE inhibitor, is administered as a prodrug and is hydrolyzed to the pharmacologically active diacid, fosinoprilat. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 40-43 1283427-8 1992 In a comparison of the angiotensin-converting enzyme (ACE) inhibitors, captopril, lisinopril, and fosinopril, only fosinopril increased stroke volume, peak ejection rate, and peak filling rate, and decreased time to peak ejection rate. Fosinopril 115-125 angiotensin I converting enzyme Homo sapiens 54-57 1283429-0 1992 Fosinopril: a new generation of angiotensin-converting enzyme inhibitors. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 32-61 1283429-1 1992 Fosinopril, the first agent in a new chemical class of phosphorus-containing angiotensin-converting enzyme (ACE) inhibitors, has unique pharmacologic properties. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 77-106 1283429-1 1992 Fosinopril, the first agent in a new chemical class of phosphorus-containing angiotensin-converting enzyme (ACE) inhibitors, has unique pharmacologic properties. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 108-111 1283429-2 1992 Fosinopril administration leads to complete inhibition of plasma ACE activity for 12-24 h. In patients with normal renal function, approximately equal amounts of the drug are eliminated via the hepatic and renal routes. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 65-68 1834450-0 1991 Fosinopril (Staril)--another ACE inhibitor. Fosinopril 12-18 angiotensin I converting enzyme Homo sapiens 29-32 1652404-1 1991 The phosphinyl ester prodrug fosinopril, a new angiotensin converting enzyme (ACE) inhibitor, is fully hydrolysed after oral administration to the pharmacologically active diacid, fosinoprilat. Fosinopril 29-39 angiotensin I converting enzyme Homo sapiens 47-76 1652404-1 1991 The phosphinyl ester prodrug fosinopril, a new angiotensin converting enzyme (ACE) inhibitor, is fully hydrolysed after oral administration to the pharmacologically active diacid, fosinoprilat. Fosinopril 29-39 angiotensin I converting enzyme Homo sapiens 78-81 1826651-1 1991 Single-dose kinetics of fosinopril, a new phosphorus-containing angiotensin-converting enzyme inhibitor and its active diacid, fosinoprilat, were investigated in patients with mild, moderate, or severe renal impairment and in those with normal renal function. Fosinopril 24-34 angiotensin I converting enzyme Homo sapiens 64-93 1826651-5 1991 The dual elimination of fosinoprilat by the liver and the kidney distinguishes fosinopril from other angiotensin-converting enzyme inhibitors. Fosinopril 24-34 angiotensin I converting enzyme Homo sapiens 101-130 1646240-0 1991 Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects. Fosinopril 55-72 angiotensin I converting enzyme Homo sapiens 77-106 1835932-6 1991 Serum ACE activity remained significantly suppressed at 24 and 48 h after fosinopril sodium administration with mean decreases from baseline of 94.2% and 70.6%, respectively. Fosinopril 74-91 angiotensin I converting enzyme Homo sapiens 6-9 1646240-13 1991 These data show that fosinopril is a safe and effective inhibitor of ACE with a long duration of action on serum ACE activity. Fosinopril 21-31 angiotensin I converting enzyme Homo sapiens 69-72 1646240-13 1991 These data show that fosinopril is a safe and effective inhibitor of ACE with a long duration of action on serum ACE activity. Fosinopril 21-31 angiotensin I converting enzyme Homo sapiens 113-116 2142429-1 1990 The effect of the angiotensin converting enzyme (ACE) inhibitor fosinopril sodium on regional cerebral blood flow (rCBF) was investigated in 8 patients with moderate essential hypertension. Fosinopril 64-81 angiotensin I converting enzyme Homo sapiens 49-52 2148357-12 1990 Reduction of GFR, restoration of response to API and reduction of proteinuria, indicate that ACE inhibition with fosinopril ameliorates HF and GH. Fosinopril 113-123 angiotensin I converting enzyme Homo sapiens 93-96 2207707-2 1990 ACE inhibitors and thiorphan competed to a similar level for the [3H]SQ29,852 binding site in the human temporal cortex with a rank order of affinity (pKi values mean +/- S.E.M., n = 3), lisinopril (9.49 +/- 0.02), captopril (9.16 +/- 0.08), SQ29,852 (8.58 +/- 0.04), epicaptopril (7.09 +/- 0.08), fosinopril (7.08 +/- 0.05) and thiorphan (6.40 +/- 0.04). Fosinopril 298-308 angiotensin I converting enzyme Homo sapiens 0-3 24556825-4 2014 METHODS: This double-blind, randomized placebo-controlled trial investigated the effect of the ACE inhibitor, fosinopril, on quadriceps function in patients with COPD with quadriceps weakness. Fosinopril 110-120 angiotensin I converting enzyme Homo sapiens 95-98 25845252-5 2015 RESULTS: ACE inhibitors protein binding data varied from negligible (lisinopril) to 99% (fosinopril). Fosinopril 89-99 angiotensin I converting enzyme Homo sapiens 9-12 25188759-3 2014 The HRV spectral indices and the index S of synchronization between the 0.1-Hz rhythms in HR and PPG during a tilt test are compared in their ability to control the AT with angiotensin-converting enzyme inhibitors (ACE-Is) (fosinopril or enalapril) and beta-blockers (atenolol or metoprolol). Fosinopril 224-234 angiotensin I converting enzyme Homo sapiens 215-218 34458381-7 2021 Results: The ACE inhibitors and their analogues fosinopril (1-), fosinopril and moexipril have the best binding affinity to the protein with binding energies < - 7.0 kcal/mol while non-flavonoid stilben-4-ol binds with free binding energy of - 7.1 kcal/mol. Fosinopril 48-58 angiotensin I converting enzyme Homo sapiens 13-16 34458381-7 2021 Results: The ACE inhibitors and their analogues fosinopril (1-), fosinopril and moexipril have the best binding affinity to the protein with binding energies < - 7.0 kcal/mol while non-flavonoid stilben-4-ol binds with free binding energy of - 7.1 kcal/mol. Fosinopril 65-75 angiotensin I converting enzyme Homo sapiens 13-16 2970855-0 1988 Effects of fosenopril, a once-daily angiotensin-converting enzyme inhibitor, on resting and exercise-induced changes of blood pressure, hormonal variables, and plasma potassium in essential hypertension. Fosinopril 11-21 angiotensin I converting enzyme Homo sapiens 36-65 2970855-1 1988 Fosenopril, a new angiotensin-converting enzyme (ACE) inhibitor, is a prodrug that is converted to its active diacid metabolite after intestinal absorption. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 18-47 2970855-1 1988 Fosenopril, a new angiotensin-converting enzyme (ACE) inhibitor, is a prodrug that is converted to its active diacid metabolite after intestinal absorption. Fosinopril 0-10 angiotensin I converting enzyme Homo sapiens 49-52 2836111-3 1988 Three chemical classes of angiotensin converting-enzyme inhibitors have been introduced into clinical use, the sulfhydryl-containing inhibitors such as captopril and its analogs and prodrugs, carboxyalkyldipeptides such as enalapril and its analogs, and phosphorus-containing inhibitors such as fosinopril and the phosphonate SQ 29,852. Fosinopril 295-305 angiotensin I converting enzyme Homo sapiens 26-55 2967089-1 1988 1 Fosinopril sodium is the first phosphorus-containing angiotensin-converting enzyme (ACE) inhibitor to be studied clinically as an antihypertensive agent. Fosinopril 2-19 angiotensin I converting enzyme Homo sapiens 55-84 2967089-1 1988 1 Fosinopril sodium is the first phosphorus-containing angiotensin-converting enzyme (ACE) inhibitor to be studied clinically as an antihypertensive agent. Fosinopril 2-19 angiotensin I converting enzyme Homo sapiens 86-89 32991443-6 2020 INTERVENTIONS: The patient was treated using metoprolol (23.75 mg qd) and angiotensin-converting enzyme inhibitor (fosinopril sodium 5 mg qd). Fosinopril 115-125 angiotensin I converting enzyme Homo sapiens 74-103 25383221-1 2014 The purpose of the present study was to determine the angiotensin-I converting enzyme inhibitory activity of few novel Fosinopril derivatives which were predicted to possess better ACE inhibitory activity and lesser side effects than the existing drug molecule. Fosinopril 119-129 angiotensin I converting enzyme Homo sapiens 54-85 24986000-13 2014 Noteworthy, the American guidelines introduce also ACE inhibitors - fosinopril and quinapril, on the other hand beta-blockers don t involve nebivolol. Fosinopril 68-78 angiotensin I converting enzyme Homo sapiens 51-54 25383221-1 2014 The purpose of the present study was to determine the angiotensin-I converting enzyme inhibitory activity of few novel Fosinopril derivatives which were predicted to possess better ACE inhibitory activity and lesser side effects than the existing drug molecule. Fosinopril 119-129 angiotensin I converting enzyme Homo sapiens 181-184 25383221-2 2014 In vitro study was carried out to determine ACE inhibitory activity of six different Fosinopril analogs by spectrophotometric assay procedure. Fosinopril 85-95 angiotensin I converting enzyme Homo sapiens 44-47 20617288-1 2010 OBJECTIVES: The present study evaluates the effects of a 6-month treatment with an ACE-inhibitor (ie, fosinopril) on serum concentrations of total IGF-1 and IGF binding protein (IGFBP)-3 in older adults at high risk for cardiovascular disease. Fosinopril 102-112 angiotensin I converting enzyme Homo sapiens 83-86 20617288-9 2010 Serum concentrations of total IGF-1 were significantly higher after 6-month treatment with fosinopril compared to placebo (203.73 ng/mL vs 194.24 ng/mL; p=0.02): After ACE-inhibitor intervention, significantly higher serum IGFBP-3 concentrations compared to controls (4308.81 ng/mL vs 4086.93 ng/mL; p=0.03) were also reported. Fosinopril 91-101 angiotensin I converting enzyme Homo sapiens 168-171 19185642-2 2009 The present study evaluates effects of an ACE inhibitor (ie, fosinopril) intervention on novel cardiovascular risk factors. Fosinopril 61-71 angiotensin I converting enzyme Homo sapiens 42-45